** WARNING, Not error free yet, under construction: check result to a standard work. **

Difference between revisions of "Quetiapine"

From MedicaWiki
Jump to: navigation, search
[checked revision][checked revision]
Line 36: Line 36:
 
| cth = 50-500
 
| cth = 50-500
 
| cth_ref = {{UMCGTox}}
 
| cth_ref = {{UMCGTox}}
| price = 0
+
| price = 3
| price_ref = <ref>oraal  9,10/maand/DDD cf FTK: results in &euro;0.30 </ref>
+
| price_ref = <ref>oraal  95,10/maand/DDD cf FTK: results in &euro;3.17 </ref>
  
 
| <!-- caution areas -->
 
| <!-- caution areas -->

Revision as of 09:12, 23 May 2011

quetiapine
Type antipsychotic
Group atypical antipsychotics
links
ATC-code N05AH04
CAS-number 111974-69-7
Medscape 342984
PubChem 5002
PubMed quetiapine
Drugs.com quetiapine-fumarate
drugbank APRD00675
Kompas (nl) quetiapine
Wikipedia quetiapine
more info
DDD 400mg [1]
Cth 50-500μg/L [2]
Ctox 500μg/L [3]
EQ-dosage 0.03[4] haloperidol
T1/2 7h [5]
metabolites 8[5]
bioavailability 100%[6]
administration oral
tablets 25,50,100,150,200,300,400 mg [7][6]
Price/day 3 [8]

quetiapine is an antipsychotic in the group atypical antipsychotics.


Caution area Value Ref Description
Lactation 6 [9] Possibly unsafe
Pregnancy 5 [5] possibly unsafe - B3* - animal studies have shown fetal damage, significance in humans unknown
Diabetes mellitus 6 [7][10][11] average influence on diabetes - frequent monitoring recommended
Hepatic insufficiency 8 [5] Unsafe with mild hepatic impairment (Child-Pugh classification A - monitoring required)
Children 2 [12] applicable - not registered for pediatric use, but well studied
Elderly 6 [5][10][13] average safety - adapt dosage
Dementia 10 [10] not approved for patients with dementia
Chronic Obstructive Pulmonary Disease 8 [14][15] unsafe - adapt dosage or substitute drug
Hypertension 8 [6] common (between 1 in 10 and 1 in 100 patients: 1% - 10%)
Hypotension 8 [6][10] common (between 1 in 10 and 1 in 100 patients: 1% - 10%)
Heart failure 8 [6] strong influence on HF - rather unsafe, continue only if absolutely necessary
Long QT-syndrome 4 [5][16][17] Possible Risk of QT prolongation Arizona Scale - Possible Risk of TdP
Seizures 6 [7][10] uncommon (between 1 in 100 and 1 in 1,000 patients: 0,1% - 1%)
Cerebrovascular accidents 8 [6][7] strong influence on CVA - only applicable with frequent monitoring
Renal insufficiency 6 [18][19] unsafe when MDRD between 30 - 50 (moderate renal impairment, monitoring required)
Dyskinesia 8 [6][13] common (between 1 in 10 and 1 in 100 patients: 1% - 10%)
Movement disorders 10 [6][10] very common (over 1 in 10 patients: > 10%)
Haematology 8 [5][6][10] common (between 1 in 10 and 1 in 100 patients: 1% - 10%)
Anticholinergic effects 10 [5][6][7] very common (over 1 in 10 patients: > 10%)
Male sexual dysfunction 10 [20][22] very common (over 1 in 10 patients: > 10%)
Female sexual dysfunction 10 [20][22] very common (over 1 in 10 patients: > 10%)
Traffic 6 [5][23] medium influence (category II) 0,5-0,8 g/l (0,5–0,8‰)
Weight 10 [10][24][25][26] very common (over 1 in 10 patients: > 10%)
Weight gain 0 unknown/unverified
Weight loss 0 unknown/unverified
Photosensitivity 0 unknown/unverified
Sedation 10 [21] very common (over 1 in 10 patients: > 10%)
Poor CYP2D6 metabolizer 0 unknown/unverified
Ultra rapid CYP2D6 metabolizer 0 unknown/unverified
Poor CYPC19 metabolizer 0 unknown/unverified
Ultra rapid CYP2C19 metabolizer 0 unknown/unverified


  1. WHO Collaborating Centre for Drug Statistics Methodology ATC=N05AH04
  2. Universitair Medisch Centrum Groningen, Referentiewaarden klinisch farmacologisch bepalingen
  3. NVZA; Toxicology.org; Monografie ID=73 (dutch)
  4. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics; J Clin Psychiatry 2003; 64: 663-667  (pubmed-id 12823080)
  5. 5.0 5.1 5.2 5.3 5.4 5.5 5.6 5.7 5.8 KNMP; Informatorium Medicamentorum 2009; Monografie "quetiapine" (Dutch)
  6. 6.00 6.01 6.02 6.03 6.04 6.05 6.06 6.07 6.08 6.09 6.10 Drugs.com quetiapine-fumarate
  7. 7.0 7.1 7.2 7.3 7.4 CVZ; Farmacotherapeutisch Kompas - quetiapine (dutch)
  8. oraal 95,10/maand/DDD cf FTK: results in €3.17
  9. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk, 8th edition. Lippincott Williams & Wilkins; 2008
  10. 10.0 10.1 10.2 10.3 10.4 10.5 10.6 10.7 10.8 AstraZeneca; SPC SEROQUEL * 25 mg, 100 mg, 150 mg, 200 mg, 300 mg film-coated tablets
  11. Bazire S. Psychotropic drug directory 2007. Trowbridge: Cromwell Press; 2007
  12. NKFK Kinderformularium ID=649 (dutch)
  13. 13.0 13.1 Yang CH, Tsai SJ, Hwang JP. The efficacy and safety of quetiapine for treatment of geriatric psychosis. J Psychopharmacol. 2005 Nov;19(6):661-6  (pubmed-id 16272189)
  14. Jabeen S, Polli SI, Gerber DR. Acute respiratory failure with a single dose of quetiapine fumarate. Ann Pharmacother. 2006 Mar; 40(3): 559-62. Epub 2006 Feb 7.  (pubmed-id 16467251)
  15. Trifirò G, Gambassi G, Sen EF, Caputi AP, Brea J, Sturkenboom MC. Association of community-acquired pneumonia with antipsychotic drug use in elderly patients: a nested case-control study. Ann Intern Med 2010; 152(7): 418-25  (pubmed-id 20368647)
  16. Stöllberger C, Huber JO, Finsterer J. Antipsychotic drugs and QT prolongation; Int Clin Psychopharmacol 2005; 20: 243-251  (pubmed-id 16096514)
  17. Arizona Scale
  18. Taylor D, Paton C, Kapur S. The Maudsley prescribing guidelines, 10th edition. London: Informa Healthcare; 2009
  19. Bazire S. Psychotropic drug directory 2007. Trowbridge: Cromwell Press; 2007
  20. 20.0 20.1 20.2 KNMP; Informatorium Medicamentorum 2009; Inleidende tekst "Atypische Antipsychotica" (Dutch)
  21. 21.0 21.1 ToxNet, Hazardous Substances Data Bank - 7557
  22. 22.0 22.1 Serretti A, Chiesa A. A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. Int Clin Psychopharmacol. 2011 May;26(3):130-40  (pubmed-id 21191308)
  23. The International Council on Alcohol, Drugs and Traffic Safety (ICADTS). ICADTS drug list - July 2007 (Internet)
  24. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 2007;68(suppl 1): 20-7  (pubmed-id 17286524)
  25. Cahn W, Ramlal D, Bruggeman R, de Haan L, Scheepers FE, van Soest MM et al. Prevention and treatment of somatic complications arising from the use of antipsychotics. Tijdschr Psychiatr 2008;50(9):579-91  (pubmed-id 18785105)
  26. Zheng L, Mack WJ, Dagerman KS, Hsiao JK, Lebowitz BD, Lyketsos CG et al. Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study. Am J Psychiatry 2009; 166:583-90  (pubmed-id 19369318)